arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Theravance Biopharma, Inc.

TBPH
$16.92 ▲ +0.02 (+0.12%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Theravance Biopharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $867.6M
Dividend Yield
Revenue Growth 15.0%
Op. Margin -53.6%
ROIC -2.5%
FCF / Share $1.43
Trailing P/E
Price / Book 3.0x
FCF Yield 8.5%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.70M
↑ +15.0%
Net Income Profit after all expenses
$-4.93M
↑ +63.7%
Operating Margin Operating profit as % of sales
-53.6%
↓ -222.9% 22th
FCF / Share Free cash flow per share
$1.43
↑ +65.0%
Long-Term Debt Long-term obligations
$624.70M
↑ +0.5%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
74
Returns
95
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 55 quarters